Pathology: mNSCLC - L1 - all population; mNSCLC - L1 - PDL1 positive; mNSCLC - L1 - TMB>10Mb; mNSCLC - L2 - PDL1 negative;
mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 positive | mNSCLC - L1 - TMB>10Mb | mNSCLC - L2 - PDL1 negative | |||||
MYSTIC (DT ; all population), 2020 | CheckMate 9LA, 2021 | MYSTIC (DT ; PDL1>25%), 2020 | CheckMate 227 (NI vs C ; PDL1>1%), 2018 | KEYNOTE-598, 2020 | CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 | ARCTIC (DT ; study B ; PDL1<25%), 2020 | ||
durvalumab plus tremelimumab | 3 | T1 | T1 | T1 | ||||
nivolumab plus ipilimumab | 2 | T1 | T1 | |||||
nivolumab plus ipilimumab plus SoC | 1 | T1 | ||||||
pembrolizumab plus ipilimumab | 1 | T1 | ||||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | |||
pembrolizumab plus placebo | 0 | T0 | ||||||
pemetrexed plus platin | 0 | T0 | T0 |